非布司他过敏患者成功进行非布司他脱敏治疗：马来西亚的经验
Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience.
作者信息
Sulaiman Narisa, Othman Ahmad Zaidi, Shahril Nor Shuhaila, Abdul Rashid Anna Misyail, Md Noh Mohamad Syafeeq Faeez
机构信息
Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Department of Medicine, Hospital Putrajaya, Putrajaya, Malaysia.
出版信息
SAGE Open Med Case Rep. 2017 Dec 17;5:2050313X17749080. doi: 10.1177/2050313X17749080. eCollection 2017.
Over the years, allopurinol has been widely used as the preferred choice of urate lowering therapy in patients with gout. However, its role in patients with renal impairment is limited; and adverse reactions are well documented. Febuxostat, a newer oral non-purine xanthine oxidase inhibitor has been proven in several trials to be more effective and tolerable compared to allopurinol and may be used in patients with renal impairment. Here, we describe a case of successful febuxostat desensitization in a patient with a history of allopurinol- and febuxostat-induced adverse cutaneous reaction, as well as the protocol utilized.
多年来，别嘌醇一直被广泛用作痛风患者降低尿酸治疗的首选药物。然而，它在肾功能损害患者中的作用有限；且不良反应有充分记录。非布司他是一种新型口服非嘌呤类黄嘌呤氧化酶抑制剂，多项试验已证明其与别嘌醇相比更有效且耐受性更好，可用于肾功能损害患者。在此，我们描述了一例有别嘌醇和非布司他引起的皮肤不良反应病史的患者成功进行非布司他脱敏治疗的病例，以及所采用的方案。
Zotero 插件